Human leukocyte C1q receptor binds other soluble proteins with collagen domains by unknown
T
he existence of a cell surface receptor for the comple-
ment protein Clq was first suggested in 1972 (1). The
ligand Clq has a complex structure made up ofsix globular
regions, each attached to a short collagen triple helix (2).
Clq receptor (C1gR) binds to the collagenous region of C1q
(3), but does not appear to be a general receptor for struc-
tural collagens (4). C1gR is an acidic glycoprotein with
15-20% carbohydrate (4) . The detergent-solubilized protein
is an elongated dimer of Mr 115,000 ± 7,000 and remains
soluble in the absence of detergent (4) . ClgR activity is found
on most leukocytes, endothelial cells, fibroblasts, and platelets
(5, 6), and binding of Clq to its receptor has been reported
to mediate a range of phenomena, including phagocytosis,
antibody-dependent cell-mediated cytotoxicity (ADCC),t
modulation of cytokine and immunoglobulin secretion, and
polymorph-endothelium interaction (6, 7). Recently, three
other proteins, mannan binding protein (MBP), lung surfac-
tant protein (SRA), and bovine conglutinin, which have similar
primary structure to C1q, have been characterized. Each has
collagenous and globular domains (reviewed in reference 8).
Availability of the pure receptor (4, 9) prompted examina-
tionofits possible interaction with these threeproteins, human
MBP, human recombinant SP-A, and bovine conglutinin,
which are known to be similar in ultrastructure to Clq (8)
(MBP and SP-A: Fig. 1) or to have functional association with
the complement system (10, 11) (MBP and conglutinin: Fig. 1).
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Summary
A receptor binding to the Clq subcomponent of complementhasbeen reported by many workers.
In this paper we report for the first time that Clq receptor binds not only to Clq, but also
to three other structurally similar ligands, namely mannan binding protein (MBP), conglutinin,
and lung surfactant protein (SP-A). All these ligands have been reported to enhance removal of
species bound to their globular domain from blood (MBP, conglutinin, Clq) or lung (SP-A)
through phagocytosis. One of the possible roles for ligand-receptor binding may be initiation
of phagocytosis.
Purification ofLigands.
￿
Clq used in this studywas isolated from
human serum as described by Reid (12). Clq was radioiodinated
1 Abbreviations used in this paper: ADCC, antibody-dependent cell-
mediated cytotoxicity; MBP, mannan binding protein; SP-A, lung
surfactant protein.
using a standard lodogen reaction (13). Specific activity was 1-2
x 106 cpm/hg. MBP was also isolated from human serum (14,
15) by affinity purification on a mannan Sepharose column. Frac-
tions containing MBP were further purified on a Superose 6 (Phar-
macia Ltd., Milton Keynes, UK) gel filtration column, equilibrated
and washed with 20 mM Tris/HCI buffer, pH 7.4, containing 1 M
NaCl, 1 mM EDTA, 0.01% NaN3, 0.01% Tween 20, followed by
purification on a Mono Q (Pharmacia Ltd.) FPLC ion-exchange
column.
SP-A (human, recombinant) was a generous gift from K.P.
Schafer, Byk Gulden Pharmazeutica, Konstanz, FRG. This prepa-
ration contains a single polypeptide chain type (typeOx3), although
two highly homologous polypeptides (0x2,043) may occur naturally.
Conglutinin was purified from heat-inactivated (56°C, 30 min)
bovine serumby adsorption to zymosan in the presence of 10 mM
CaCl2 (16). The zymosan was washed exhaustively with 5 mM
sodium barbitone/HCI, 145 mM NaCl, 10 mM CaCl2, pH 7.4,
then conglutinin was eluted in the same buffer containing 10 mM
EDTA in place of CaCl2. Conglutinin was precipitated by dialysis
against distilled water, dissolved in 10 mM Tris/HCl, 140 mM NaCl,
20 mM CaCl2, pH 7.4 (TBS-Ca2'), centrifuged (10,000 g, 20
min), and applied to a mannan-Sepharose column (14). The column
was washed in TBS-Ca2', then bound protein was eluted with
TBS containing 10 mM EDTA. Minor contaminants were removed
by ion-exchange on a Mono-Q (Pharmacia) column equilibrated
in 10 mM Tris/HCI, 50 mM NaCl, 1 mM EDTA, 0.05% NaN3,
pH 7,8. The column was developed with a 50-500 mM NaCl
gradient.
Proteins used were >95% pure, as assessed by SDS-PAGE in
reducing conditions (17). The polypeptide chain size of each of
the four proteins is distinct by this method, and cross-contamination
was not detected (Fig. 2).
Purification ofClq-Receptor.
￿
C1gR was purified from tonsil lym-
phocytes by the method of Malhotra and Sim (4).
Binding ofC1gR to Ligands Immobilized onMicrotiter Plates.
￿
Mi-
crotiter plate wellswere coated with 100 Al ofC1q or conglutinin
at 10 g,g/ml in 10 mM potassium phosphate, 5 mM EDTA, 100
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Ultrastructure of C1q, SP-A, conglutinin, and MBP . Clq
(a) is a hexameric structure made up of six bent collagen triple
helices joined to a globular domain. SP-A is essentially identical in
appearance in electron microscopy to C1q (8). MBP has a similar
monomer structure, but when isolated consists of a range of oligo-
mers mainly trimers and tetramers (c) and hexamers (13) . Conglutinin
(b) is a much larger protein, consisting of four subunits each made
up of a collagenous and globular region .
mM KCI,pH 7.4, for2h at room temperature . Plates were washed
in the same buffer and nonspecific binding sites were blocked with
BSA (5 mg/ml in the same buffer) . C1gR was isolated as described
previously (4) and iodinated with 125 I in a standard iodogen reac-
tion (13) . Specific activity was 0.5-4 x 10 6 cpm/hg . All binding
assays were done in 10 mM potassium phosphate, pH 7.4 .
Binding to Immobilized C1q .
￿
Serial twofold dilutions of "T
labeledC1gR (501u1 :maximum concentration 2 Ntg/ml) were prein-
cubated with 100 F1 ofpotential binding competitors soluble col-
lagen (type IV, human placental ; Sigma Chemical Co., St . Louis,
MO), MBP, SP-A, or Clq each at a constant initial concentration
of 50 Fig/ml), for 30 min at 37°C in the 10 mM potassium phos-
phate buffer. Acontrol with no potential inhibitor was included .
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Figure 2.
￿
Purified ligands analyzed on 7.5% SDS-PAGE and de-
tected by Coomassie Brilliant Blue staining . (Lane s) Reduced stan-
dards 1, C12-Macroglobulin (180 W) ; 2, /3-galactosidase (116 kD) ; 3,
fructose-6-phosphate kinase (84 kD) ; 4, pyruvate kinase (58 kD) ; S,
fumarase (48.5 kD); 6, lactate dehydrogenase (36.5 kD) . (Lane a)
Mannan binding protein . (Lane b) Conglutinin . (Lane c) Lung surfac-
tant protein . (Lane d) C1q .
Mixtures were then transferred to Clq-coated microtiterplate wells
and left for 2 h at ambient temperature (18-22°C) . After washing
three times with 300 p,l of 10 mM potassium phosphate buffer,
pH 7.4, bound 125I-labeled C1gR was solubilized and removed
with 400Al of 4MNaOH . Radioactivity obtained from each well
was measured on an LKB 1275 minigamma counter.
Binding to Immobilized Conglutinin .
￿
A constant quantity of 125 I-
labeled C1gR (100 ,u1 : concentration 2 /Ag/ml) was pre-incubated-
with serial twofold dilutions of the potential competitors MBP,
Clq, and conglutinin (100 Nd ;maximum concentration 12 .5 Pg/ml)
for30 min at 37°Cin 10 mM potassiumphosphate buffer. A con-
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(a) Binding of 1251-labeled C1gR to solid-phase bound Clq . Serial dilutions of 1211-labeled C1gR (50 )A1; 2 ug/ml) were preincubated
with constant concentrations (100 )t1; 50 1~g/ml) of collagen ("), Clq (O), conglutinin (0), MBP (A), SP-A (*), and loaded on to Clq-
coated microtiter plates. Details of the assay are given in Materials and Methods. (b) Binding of 1251-labeled ClgR to solid-phase bound conglu-
tinin . Serial dilutions (maximum quantity 1.25 p.g) of conglutinin (EI), MBP (A), Clq (O), BSA (A) were incubated with 125I-labeled C1gR
(100 al ; 2 Ag/ml) in 10 mM potassium phosphate buffer (pH 7.4) and loaded on to conglutinin-coated microtiter plates . After washing with
loading buffer, bound cpm in the presence or absence of competing species were measured . Details are given in Materials and Methods .
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LS P-Atrol with no potential inhibitor was included. The mixture was
transferred to conglutinin-coated microtiter plate wells. After in-
cubation and washing (as above) the "S1-labeled ClqR bound in
the presence or absence of competitor was measured, as above.
Binding of Ligands to U937 Cells.
￿
U937 cells were grown in
50-ml culture flasks in standard conditions (18). U937 (10' cells)
were washed threetimes with PBS, followed by three washes with
5 mM sodium barbitone buffer containing 5% (wt/vol) glucose,
pH 7.4 (buffer A). The cell pellet was suspended in 10 ml ofbuffer
A. Different dilutions of potential competitors of Clq binding,
namely MBP, C1q, ClgR, or conglutinin (100 pl; maximum con-
centration 50 pg/ml) were incubated with "'I-labeled C1q (100
pI; 1 pg/ml) for 30 min at 37°C in buffer A. The mixture was
incubated with 100 pl of U937 cell suspension (105 cells) for 30
min at 37°C. Unbound ligand was separated by spinning the cell
suspension through 100 pl ofdi-(n-butyl)-phthalate for 1 min at
10,000 g . Counts per minute bound to the cell pellet in the pres-
ence or absence of competitor were measured.
Binding of 1251-labeled ClqR to EAiC3b Cells.
￿
Sheep erythro-
cytes bearing bound iC3b (EAiC3b) cells were prepared by clas-
sical pathway activation followed by incubation with purified factors
H and I (19). EAiC3b cells were suspended (108 cells/ml) in 5 mM
sodium barbitone buffer (pH 7.4), containing 5% (wt/vol) glu-
cose, 0.5 MM MgC12, and 0.15 mM CaC12 (buffer B). To prepare
EAiC3b-conglutinin cells, EAiC3b (3 x 108 cells) were incubated
with 100,ug of bovine conglutinin at 37°C for 30 min and then
washed three times in buffer B. Different dilutions of '151-labeled
C1gR (100 pl; maximum concentration 2 pg/ml) were incubated
with 100 Al of EaiC3b or EAiC3b-conglutinin cells for 30 min
at 37°C. Unbound ligand was separated by spinning the cell sus-
pension through 100 Al of di-(n-butyl)-phthalate at 10000 g for
1 min. Counts per minute bound to the cell pellet were measured.
Results
Binding of 1211-labeled ClqR to Ligand Immobilized on Mi-
crotiter Plates. Dose-dependent binding of 125I-C1gR to
solid-phase immobilized Clq was observed (Fig. 3 a). As pre-
viously shown (4), this binding is saturable. Binding of the
receptor was not diminished by preincubation with soluble
type IV placental collagen, but was greatly reduced by con-
stant concentrations ofsoluble Clq, conglutinin, MBP, and
SP-A (Fig. 3 a). Direct binding of the radioiodinated ClqR
to immobilized conglutinin (Fig. 3 b) was confirmed and it
was shown that the C1gRconglutinin interaction was in-
hibited in a concentration-dependent manner by preincuba-
tion of the soluble receptor with soluble unlabeled Clq, MBP,
or conglutinin (Fig. 3 b) . Each of the three soluble proteins
inhibited over a similar concentration range. Again soluble
collagen (not shown) and BSA (Fig. 3 b) did not inhibit the
interaction.
The results shown in Fig. 3 indicate that C1q, MBP, SP-A
and conglutinin all bind to C1gR. Further studies (not shown)
confirmed direct binding of radioiodinated C1gR to micro-
titer plate-bound MBP, and inhibition of C1gR-MBP inter-
action by Clq, conglutinin, and SP-A. The cross-inhibition
of each C1gRligand interaction by each ofthe other ligands
suggests Clq, MBP, SP-A, and conglutinin bind to the same
site, or overlapping sites on C1gR. This is reinforced by the
similarityin concentration dependenceofinhibition (Fig. 3 b).
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Binding of 1111-labeled-Clq to U937 Cells.
￿
Binding assays
based only on the use ofproteins immobilized on microtiter
plates serve as a useful indication of binding specificity, but
represent a highly artificial system. Binding ofpotential ligands
to intact cells bearing C1gR, a less artificial system, was there-
fore studied. Since the binding of monomeric Clq to ClqR
is highly dependent on ionic strength (3), these tests were
done at low ionic strength to maximize binding. Binding
of radioiodinated C1q to U937 cells was inhibited in a
concentration-dependent manner by co-incubation with sol-
uble ClgR, MBP, or conglutinin (Fig. 4), indicating that
binding of Clq to the cells does occur via ClgR, and that
MBP and conglutinin compete for the same receptor. Binding
of monomeric Clq to ClqR was considerably reduced (by
-74%) at physiological salt strength compared with the low
salt conditions used here. This is consistent with the results
of Arvieux et al. (3).
Binding of1211-labeled ClqR to EAiC3b.
￿
A further intact
cell system in which binding of ClqR to conglutinin could
be examined was devised. Conglutinin is known to bind to
the complement activation product iC3b (20). Sheep erythro-
cyteswere sensitizedwith antibody (A) and coated with iC3b
(EAiC3b) usingpurified complement classical pathway com-
ponents. EAiC3b were then pre-incubated with and without
conglutinin, washed, and the binding of I'll-labeled ClqR
was assessed (Fig. 5). Cells treated with conglutinin bound
more ClqR than did cells lacking conglutinin (Fig. 5). The
moderate binding of radioiodinated ClqR in the absence of
conglutinin reflects the presence of small amounts of Clq
(used in the complement activation procedure) on these cells.
This confirms the binding of ClqR to conglutinin attached
in a physiologically relevant manner to iC3b.
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Figure 4. Binding of 12s1-labeled C1gR to U937 cells. Dilutions of
MBP (A), conglutinin (0), Clq (O), ClqR (/), BSA (") (max-
imum quantity 5 pg) were premixed with 1251-labeled ClqR and
then incubated with U937 cell (105 cells) in 5 mM barbitone buffer
(pH 7.4) containing 5% (wt/vol) glucose. Bound cpm in the pres-
ence and absence of competing species were measured, as described in
Materials and Methods.100000-1
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￿
Binding of 1251-labeled C1gR to EAiC3b cells in the
presence or absence of conglutinin. EAiC3b cells were preincubated
with (p) or without (+) conglutinin as described in Materials and
Methods, then exposed to 1251-labeled C1gk in sodium barbitone
buffer (pH 7.4) containing 5% (wt/vol) glucose. Unbound ligand
was separated and cpm bound to cells were measured on an LKB
gamma counter.
In this studywe have demonstrated that binding to C1gR
is a common function of four different proteins, which were
not, with the exception of C1q and MBP, previously known
to have strong functional similarities. Their structuralsimilarity
is, however, evident (Fig. 1). All of these proteins contain
polypeptide chains made up of a short, NH2-terminal non-
collagen-like sequence, followed by a collagenous region of
repeating Gly-Xaa-Yaa sequence, and a COOH-terminal end
containing a recognition domain (8). Since C1gR is known
to bind to the collagenous region of C1q (3), it is likely that
it binds to the collagenous segments of MBP, SP-A, and con-
glutinin.
The established Lgand, C1q, is a well-characterized pro-
tein that initiates activation of the classical complement
pathway (2) . It also functions as an opsonin, by interaction
with C1gR on phagocytec cells (6). The soluble MBP used
here occurs as a traceprotein in serum (8, 14). It has a C-type
lectin domain in the COOH-terminal region of the poly-
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peptide, and binds to mannose/N-acetyl-D-glucosamine-con-
taining structures, particularly yeast mannns, and also to
mannose-rich surface polysaccharides on HIV and on viru-
lent gram-negative bacteria (8, 21, 22). Its role as an opsonin
in clearance of wild-type virulent Salmonella montevideo has
been examined (21). Our results strongly suggest that the
opsonic function of this protein is mediated by interaction
with C1gR on phagocytes. Serum MBP when bound to, for
example, yeast mannan, is also now known to mediate acti-
vation of the complement classical pathway (11, 14), and pos-
sibly also the alternative pathway (23), so in vivo its direct
opsonic activity may be less significant than its role in
stimulating deposition ofanother highly effective opsonin, C3.
SPA is a major protein ofpulmonary surfactant. Like MBP,
it contains a C-type lectin domain within the primary se-
quence (8) and it has been indicated that it serves as an op-
sonin (24). It is thought to have a Cal+-dependent man-
nose/fucose specificity (8). The "target" for its lectin activity
is unknown, but our results suggest that one of its functions
may be to stimulate phagocytosis of material deposited in
the lung, via interaction with C1gR on lung macrophage.
Conglutinin has until recently been considered as an ob-
scure tracebovine serum protein. It has been detected in human
plasma, again at very low levels (25) . It has Cal+-dependent
lectin activity ofspecificity similar to that ofMBP, and binds
directly to some yeasts (8, 10, 20, 25, 26) . Its interaction
with mannose-rich oligosaccharide on the complement acti-
vation fragment iC3b is well established (20). Opsonic (anti-
bactericidal) activity has been demonstrated for conglutinin,
although this effect appears to depend on prior deposition
of iC3b on bacteria (10). Again our results suggest that the
opsonic activity of conglutinin may be mediated by interac-
tion with C1gR.
Demonstration ofthe interaction ofC1q, MBP, SP-A, and
conglutinin with C1gR strongly suggests a similar function
for these structurally related proteins. The rodent protein
RaRF (27) may be a further member of this family, both
in terms ofactivity and structure. In addition to having roles
as opsonins the newly identified C1gR ligands may be ex-
pected to mediate other phenomena associatedwith C1q-C1gR
interaction.
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